Navigating migraine care through the COVID-19 pandemic: an update

Angus‐Leppan, Heather; Guiloff, Angelica E; Benson, Karen; Guiloff, R J

doi:10.1007/s00415-021-10610-w

Cited by 11 publications

(13 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] .…”

Section: Uncited Referencesunclassified

See 1 more Smart Citation

The impacts of masks and disinfectants on migraine patients in the COVID-19 pandemic

Yüksel

Kenar

Gursoy

et al. 2022

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Since the onset of the COVID-19 pandemic, the use of personal protective equipment (PPE) and disinfectants has become necessary to prevent transmission of the virus. However, the effects of such pandemic obligations on chronic diseases such as migraine have not been fully elucidated. We aimed to investigate the effects of the COVID-19 pandemic, as well as the use of masks and disinfectants, on migraine patients. A total of 310 migraine patients were included. Demographic data, migraine characteristics, and mask and disinfectant use were obtained through a face-to-face survey. Patients were grouped as worsening, stable, or improving according to pre-pandemic and pandemic migraine characteristics. Migraine worsening was found in 177 (57.1%) patients, stable course in 96 (31%) patients, and improvement in 37 (11.9%) patients. The use of scalp contact masks and double masks and daily mask duration were higher in the worsening group (p:0.005, p:0.005 and p:0.001). In addition, the frequency of personal disinfectant use was higher in this group (p:0.011). In regression analysis, mask type, daily mask duration, presence of allodynia, being a health worker, depression score, and odor were determined as independent risk factors for migraine worsening. We found a worsening of migraines in more than half of patients during the COVID-19 pandemic. We also demonstrated a relationship between migraine worsening and mask type, number of masks, and intensive disinfectant use. Migraine patients should be advised of optimal prevention methods based on individual social and working conditions rather than exaggerated preventative measures.

show abstract

“… [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] .…”

Section: Uncited Referencesunclassified

“…At present, it is not possible to fully predict the impacts and consequences on chronic diseases of either this global threat itself or the pandemic restrictions. However, it is well understood that COVID-19 has significant effects on patients with chronic diseases that require regular follow-up and treatment [2,3].…”

Section: Introductionmentioning

confidence: 99%

The impacts of masks and disinfectants on migraine patients in the COVID-19 pandemic

Yüksel

Kenar

Gursoy

et al. 2022

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

show abstract

“…Reports from the three countries for the third week of June 2020 showed that the estimated number of deaths in Mexico was around seventeen thousand, in Peru, about eight thousand, and in Argentina, about one thousand. However, by the fifth month of lockdown, there was an effect of fear of COVID-19 regarding worsening migraine symptoms as the pandemic advanced [ 12 , 17 , 18 , 19 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 Pandemic Lockdown on Migraine Patients in Latin America

Reyes-Álvarez¹,

Bancalari

Vargas

et al. 2023

IJERPH

View full text Add to dashboard Cite

The coronavirus (COVID-19) pandemic, confinement, fear, lifestyle changes, and worldwide health care impacted almost all diseases. Reports from countries outside Latin America revealed differences in migraine patients. In this study, we describe and compare the immediate changes in migraine symptoms associated with COVID-19 quarantine in patients from Argentina, Mexico, and Peru. An online survey was conducted from May to July 2020. The survey was answered by 243 migraine patients, with questions related to sociodemographic data, quarantine conditions, changes in working conditions, physical activity, coffee intake, healthcare access, acute migraine medication use, symptoms of anxiety, depression, and fear of COVID-19. The results show that 48.6% of migraine patients experienced worsened symptoms, 15.6% improved, and 35.8% remained unchanged. Worsening migraine symptoms were associated with staying at home during the lockdown. Intake of analgesics was associated with an increase in migraine symptoms of 18 times relative to those who did not increase their intake. Migraine symptoms improved when the number of sleep hours was increased, and we observed an improvement when patients decreased analgesic intake. The uncertainty about the end of the pandemic, the news, and social media are three items that contributed to the worsening of migraine symptoms in patients in the three investigated countries. Confinement during the first pandemic wave in Latin America harmed migraine patients who stayed home during the lockdown.

show abstract

“…In general, RCTs in eHealth are few despite occurrence of the COVID-19 pandemic situation, which has demonstrated a need for more evidence-based knowledge about the use of digital health technology in evaluating treatment effect, safety, and other aspects of patient management [34][35][36][37]. Patient education programs [38,39]; evaluation of psychological distress using teletechnology in diabetes [40]; use of mobile in suboptimal health [41], surgery care, and follow-up [42][43][44]; aphasia [44]; HIV consultations [38]; cancer symptom monitoring [45]; motor and cognitive function in stroke [46]; and COVID-19 follow-up [47] are areas where RCTs are used.…”

Section: Comparison With Prior Workmentioning

confidence: 99%

One-Year Remission Rate of Chronic Headache Comparing Video and Face-to-Face Consultations by Neurologist: Randomized Controlled Trial

Bekkelund¹,

Müller²

2021

J Med Internet Res

View full text Add to dashboard Cite

Background Chronic headache causing severe headache-related disability for those affected by the disease is under- or misdiagnosed in many cases and therefore requires easy access to a specialist for optimal health care management. Objective The goal of the research is to determine whether video consultations are noninferior to face-to-face consultations in treating chronic headache patients referred to a specialist in Northern Norway. Methods Patients included in the study were recruited from general practice referrals to a specialist at a neurological department in Northern Norway (Tromsø) and diagnosed according to the International Headache Society classification system. In a randomized controlled design, the 1-year remission rate of chronic headache (change from ≥15 to <15 headache days per month during the last 3 months), patient satisfaction with a specialist consultation, and need for follow-up consultations by general practitioners were compared between groups consulted by video and face-to-face in a post hoc analysis. Data were collected by interview (baseline) and questionnaire (follow-up). Results From a baseline cohort of 402 headache patients consecutively referred from general practice to a specialist over 2.5 years, 58.0% (233/402) were classified as chronic headache and included in this study. Response rates were 71.7% (86/120) in the video group and 67.3% (76/113) in the face-to-face group. One-year remission from chronic headache was achieved in 43.0% (37/86) in the video group and 39.5% (30/76) in the face-to-face group (P=.38). Patient satisfaction with consultations were 86.5% (32/37; video) and 93.3% (28/30; face-to-face; P=.25). A total of 30% (11/37) in the video group and 53% (16/30) in the face-to-face group consulted general practitioners during the follow-up period (P=.03), and median number of consultations was 1 (IQR 0-13) and 1.5 (IQR 0-15), respectively (P=.19). Conclusions One-year remission rate from chronic headache was about 40% regardless of consultation form. Likewise, patient satisfaction with consultation and need for follow-up visits in general practice post consultation was similar. Treating chronic headache patients by using video consultations is not inferior to face-to-face consultations and may be used in clinical neurological practice. Trial Registration ClinicalTrials.gov NCT02270177; https://clinicaltrials.gov/ct2/show/NCT02270177

show abstract

Navigating migraine care through the COVID-19 pandemic: an update

Cited by 11 publications

References 68 publications

The impacts of masks and disinfectants on migraine patients in the COVID-19 pandemic

The impacts of masks and disinfectants on migraine patients in the COVID-19 pandemic

Impact of COVID-19 Pandemic Lockdown on Migraine Patients in Latin America

One-Year Remission Rate of Chronic Headache Comparing Video and Face-to-Face Consultations by Neurologist: Randomized Controlled Trial

Contact Info

Product

Resources

About